The U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb's combination therapy for treating colorectal cancer in patients with a specific gene mutation. The therapy, which includes KRAZATI® (adagrasib) in combination with Cetuximab, has been granted accelerated approval for adult patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer. This approval marks a significant advancement in the treatment options available for this patient population. $BMY
Immunosuppressant Ruxolitinib Boosts Checkpoint Inhibitor Response in Patients with Hodgkin Lymphoma, Phase I Data Show. Learn more: https://t.co/CncQBsDtfM https://t.co/C9HTndzSMP
Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma. @MikeSerzanMD @DanaFarber #kcsm https://t.co/YmXmmSIkKY
The National Medical Products Administration in China has accepted the biologics license application for zanidatamab for the second-line treatment of patients with HER2-positive biliary tract cancer. #oncology #medtwitter https://t.co/2HXkA6LFjd https://t.co/HDQClwZAVm
The @EU_Commission has approved single-agent alectinib for use as adjuvant treatment after tumor resection in adult patients with ALK-positive non–small cell lung cancer at high risk of recurrence. #lcsm #oncology https://t.co/DnJXPYQ7b8
For which type of cancer was Augtyro™ @US_FDA approved recently? #LARVOL #Augtyro #FDA #CancerResearch #Onocology
The oncolytic immunotherapy RP1 in combination with nivolumab displayed activity in patients with melanoma who failed prior anti–PD-1 treatment, according to updated findings from the phase 2 IGNYTE trial. #melsm #oncology https://t.co/cy6uzaRnDA https://t.co/1yNrolQXFc
Final results from the phase 2 CORE-001 trial showed that cretostimogene grenadenorepvec plus pembrolizumab maintained a high CR rate in patients with BCG-unresponsive, high-risk NMIBC with carcinoma in situ. #blcsm #oncology #ASCO2024 https://t.co/vra2ELLdIw https://t.co/ZCQbE86TeP
Combination therapies, particularly those involving immunotherapy, have improved OS and PFS in clear cell RCC. @huntsmancancer @ASCO #kcsm #ASCO24 https://t.co/Chw4Who25i
David A. Braun, MD, PhD, highlights the developing role of T-cell therapies in RCC and looks toward the horizon for other advances. @BraunMDPhD @DanaFarberNews #kcsm https://t.co/Iu71xvjmNH
Osimertinib significantly improved PFS in unresectable, stage III NSCLC with EGFR mutations post-chemoradiotherapy. @us_fda #lcsm https://t.co/lQ4huQCErc https://t.co/vt096ALK5X
Benjamin L. Maughan, MD, PharmD, dives into key studies in RCC regarding biomarkers and first-line treatments presented at the 2024 ASCO Annual Meeting. @huntsmancancer @ASCO #ASCO2024 https://t.co/sbVRbO8HN5
In a matching-adjusted indirect comparison, linvoseltamab elicited efficacy outcomes equivalent to those seen with teclistamab-cqyv in triple-class–exposed, R/R multiple myeloma, according to findings . @TischCancer #oncology #medtwitter #ASCO24 https://t.co/7bCelOAQid
Imetelstat has gained FDA approval for adults with low- to intermediate-1–risk MDS and transfusion-dependent anemia who require 4 or more RBC units over 8 weeks and have not responded to, lost response to, or are ineligible for ESAs. @US_FDA #oncology https://t.co/hrNm6jeP6i https://t.co/wgxFCRf1gt
Mirvetuximab soravtansine-gynx produced an ORR of 51.9% and a median duration of response of 8.25 months in heavily pretreated patients with FRα-positive, platinum-sensitive ovarian cancer in the PICCOLO trial. @DukeCancer #ovca #oncology https://t.co/NbKesEbsd9
Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in @JCO_ASCO. Impressive activity among pts with HER2+ (ORR 76%, left) and HER2-low (ORR 60%, right) MBC, & in multiple other tumor types. ILD: 2.6%, 13 deaths due to AEs (4.2%), 4 treatment-related (1.3%). https://t.co/ntpTm683am https://t.co/9JuhX4Bv66
A treatment combination of dorstarlimab + carboplatin and paclitaxel led to PFS and OS benefits in patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer. #gyncsm #oncology https://t.co/VIJPIzygb7
Treatment with pembrolizumab plus platinum-based therapy elicited safe and efficacious outcomes in patients with penile squamous cell carcinoma, according to data from the single-arm phase 2 HERCULES trial. @ASCO #ASCO24 #oncology #sarcoma https://t.co/HuR2SNci6u https://t.co/locxcXGIGH
Higher T-cell inflamed gene expression profile values were positively associated with clinical outcomes for pembrolizumab plus axitinib and angiogenesis had a positive association with outcomes for sunitinib in patients with ccRCC. @ASCO #ASCO24 #kcsm https://t.co/YNF7ThvcDa https://t.co/68FM2pi0Pb
Findings from the phase 3 PRESTO trial showed improved PSA PFS while maintaining quality of life for patients experiencing biochemical recurrence post-primary treatment. #pcsm #oncology #ASCO2024 https://t.co/W5rdxjcYtb https://t.co/PhGJzNxIQz
The FDA granted fast track drug designation to lunresertib plus camonsertib as a potential treatment for adult patients with platinum-resistant ovarian cancer harboring CCNE1 amplifications, FBXW7 mutations, or PPP2R1A mutations. @US_FDA #ovca #oncology https://t.co/3eEOCTHTVJ https://t.co/Dw5o7yj7KA
The combination of teclistamab, daratumumab, and lenalidomide generated high efficacy with a 92.3% overall response rate in patients with newly diagnosed multiple myeloma. @CHU_Lille @ASCO #ASCO24 #mmsm https://t.co/3PzuS2JBDk https://t.co/3PzuS2JBDk
Menin inhibitors show promise for AML subtypes with KMT2A/MLL rearrangements and NPM1 mutations. @EuniceWangMD @RoswellPark #leusm https://t.co/psDIgLttcS https://t.co/JgSZ49HHnl
RP1, an oncolytic immunotherapy, combined with nivolumab achieved a 33.6% objective response rate in patients with melanoma who had progressed on PD-1 inhibitors. #melsm #oncology https://t.co/cy6uzaRnDA
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) $BMY https://t.co/4bL8fWIzaw
Cretostimogene grenadenorepvec plus pembrolizumab achieved a 12-month CR rate of 57% and an any-time CR rate of 83% in patients with BCG-unresponsive, high-risk NMIBC with carcinoma in situ. #blcsm #oncology #ASCO2024 https://t.co/vra2ELLdIw
Results from a new study uncovered a way to exploit drug side effects to prime #tumors to support better responses to #immunotherapy. Keep reading: https://t.co/jTGCDjeguW https://t.co/bk6UHxcYk5
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's combination therapy for treating colorectal cancer in patients with a specific gene mutation, the health regulator said on Friday. https://t.co/zapaPmzLFf https://t.co/zapaPmzLFf
As combination therapies have changed the management of ccRCC over the years, investigators are parsing out which combinations are the most effective and safe. @huntsmancancer @ASCO #kcsm #ASCO24 https://t.co/Chw4Who25i https://t.co/4tjS8FWKiF
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer @PignataSandro @myESMO #ESMOGynae24 #gyncsm https://t.co/7vhvcuxwOl